VACCINATION IN RHEUMATOLOGY: EVOLUTION OF VIEWS ON THE PROBLEM
https://doi.org/10.21518/2079-701X-2017-5-142-147
Abstract
In the present-day rheumatology, comorbid infections represent a relevant issue; their formation is caused both by the rheumatic disease (RD) and the need to use drugs with immunosuppressive action. Numerous problems caused by infections in rheumatology and other branches of clinical medicine can not be solved only by using a large number of anti-infective drugs that are available today. Therefore, in the near future, a critical role will belong to the development, improvement and prompt (if possible) introduction of various vaccines into clinical practice. The current review touches upon questions relating to the use of vaccines against influenza and pneumococcal infections in patients with RD, and formulates the prospects for further implementation of vaccination in rheumatology.
About the Authors
B. S. Belov
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
MD
M. S. Naumtseva
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
MD
G. M. Tarasova
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
PhD in Medicine
References
1. Ranjan P et al. Immunization in Patients with Rheumatic Diseases: A Practical Guide for General Practitioners. Journal of Clinical and Diagnostic Research, 2015, 9(5): OE01-OE04.
2. Bernatsky S, Hudson M, Suissa S. Antirheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford), 2007, 46(7): 1157-1160.
3. Franklin J et al. Risk and predictors of infection leading to hospitalisation in a large primarycare-derived cohort of patients with inflammatory polyarthritis. Annals of the rheumatic diseases, 2007, 66(3): 308-312.
4. Kroesen S et al. Serious bacterial infections in patients with rheumatoid arthritis under antiTNF-alpha therapy. Rheumatology, 2003, 42(5): 617-621.
5. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. Journal of epidemiology and community health, 2012, 66(12): 1177-1181.
6. Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. М.: МДB, 2009. 252 с.
7. Bernatsky S, Hudson M, Suissa S. Antirheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford), 2007, 46(7): 1157-1160.
8. Coyne P et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. The Journal of rheumatology, 2007, 34(9): 1832-1836.
9. Lanternier F et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Annals of the rheumatic diseases, 2008, 67(7): 1047.
10. Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Annals of the rheumatic diseases, 2007, 66(6): 837-838.
11. Dougados M et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, crosssectional study (COMORA). Annals of the rheumatic diseases, 2014, 73(1): 62-68.
12. Atzeni F et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmunity reviews, 2012, 12(2): 225-229.
13. Kuroda Y et al. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomedicine & pharmacotherapy, 2004, 58(5): 325-337.
14. Bach JF. Protective role of infections and vaccinations on autoimmune diseases. Journal of autoimmunity, 2001, 16(3): 347-353.
15. Brodman R et al. Influenzal vaccine response in systemic lupus erythematosus. Annals of internal medicine, 1978, 88(6): 735-740.
16. Herron A et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. Journal of the American Medical Association, 1979, 242(1): 53-56.
17. Croft SM et al. Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosu. The Journal of rheumatology, 1984, 11(2): 141-146.
18. Battafarano DF et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis and rheumatism, 1998, 41(10): 828-834.
19. Mercado U. Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus? The Journal of rheumatology, 2006, 33(8): 1469-1471.
20. Kaine JL et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. The Journal of rheumatology, 2007, 34(2): 272-279.
21. Kapetanovic MC et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford), 2006, 45(1): 106-111.
22. Mori S et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Annals of the rheumatic diseases, 2013, 72(8): 1362-1366.
23. Bingham CO 3rd et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Annals of the rheumatic diseases, 2015, 74(5): 818-822.
24. Burmester GR et al. Tofacitinib, an oral Janus kinase inhibitor: safety comparisonin patients with rheumatoid arthritis and an inadequate response to nonbiologic or biologic diseasemodifying anti-rheumatic drugs. Arthritis and rheumatism, 2013, 65(10 Suppl): 192.
25. Hua C et al. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis care and research, 2014, 66(7): 1016-1026.
26. Kapetanovic MC et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis research and therapy, 2013, 15(5): R171.
27. Schiff M et al. Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the arrive trial. Annals of the rheumatic diseases, 2007, 66(Suppl. II): 437.
28. Pham T et al. Abatacept therapy and safety management. Joint, bone, spine: revue du rhumatisme, 2009, 76(Suppl. 1): 3-84.
29. Winthrop KL et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Annals of the rheumatic diseases. http://ard.bmj.com/content/early/2015/03/20/annrheumdis-2014-207191.full.
30. Kapetanovic MC et al. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis research and therapy, 2013, 15(1): R1.
31. Plotkin SA. Correlates of protection induced by vaccination. Clinical and vaccine immunology, 2010, 17(7): 1055-1065.
32. Kavanaugh A. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. Current opinion in rheumatology, 2009, 21(4): 419-424.
33. Brezinschek HP et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Current opinion in rheumatology, 2008, 20(3): 295-299.
34. Bengtsson C et al. Commonvaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Annals of the rheumatic diseases, 2010, 69(10): 1831-1833.
35. Наумцева М.С. Оценка иммуногенности и безопасности 23-валентной полисахаридной пневмококковой вакцины у больных ревматоидным артритом. Автореферат дис. ... канд. мед. Москва, 2016, 22 стр.
36. Bijl M et al. Vaccination of patients with autoimmune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmunity reviews, 2012, 11(8): 572-576.
37. Ferreira I, Isenberg D. Vaccines and biologics. Annals of the rheumatic diseases, 2014, 73(8): 1446-1454.
38. Perry LM. Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis. Current rheumatology reports, 2014, 16(8): 431.
Review
For citations:
Belov BS, Naumtseva MS, Tarasova GM. VACCINATION IN RHEUMATOLOGY: EVOLUTION OF VIEWS ON THE PROBLEM. Meditsinskiy sovet = Medical Council. 2017;(5):142-147. (In Russ.) https://doi.org/10.21518/2079-701X-2017-5-142-147
Views:
1979
Email this article 